✦ LIBER ✦

A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours

✍ Scribed by Ann L Jackman; Camille J Melin; Rosemary Kimbell; Lisa Brunton; G.Wynne Aherne; Davinder S Theti; Mike Walton

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I and pharmacokinetic study of t

✍ Garry H. Schwartz; Christopher B. Jones; Mitchell Garrison; Amita Patnaik; Chris 📂 Article 📅 2004 🏛 Springer US 🌐 English ⚖ 145 KB

Vatalanib: the clinical development of a

✍ Scott, Edwina N; Meinhardt, Gerold; Jacques, Christian; Laurent, Dirk; Thomas, A 📂 Article 📅 2007 🏛 Informa plc 🌐 English ⚖ 276 KB

Dasatinib: A potent SRC inhibitor in cli

✍ John Araujo; Christopher Logothetis 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 345 KB

Column-switching high-performance liquid

✍ Cristi L. Hamilton; Jeffrey A. Kirkwood 📂 Article 📅 1994 🏛 Elsevier Science ⚖ 490 KB

A phase I and pharmacokinetic study of O

✍ A. R. Clamp; P. Schöffski; J. W. Valle; R. H. Wilson; S. Marreaud; A.-S. Govaert 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 315 KB

Harmonization of clinical trial guidelin

✍ L. M. ALEDORT 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB